JDRF Awards $9 Million US for Phase 3 Type 1 Diabetes Kidney Disease
New York, New York and Montreal, Quebec--(Newsfile Corp. - January 22, 2024) - JDRF, the leading global type 1 diabetes (T1D) research and
Source: thewhig.com
📰 David Cherney News
David Cherney News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from David Cherney. Real-time updates on events, politics, business and more.
Drug Protects Kidneys, Heart in Diabetic Patients
A recent Canadian study has found that a drug prescribed to treat heart failure could protect kidney and heart health in individuals with type 2 diabetes and chronic kidney disease. Results from the study were presented on November 4, at ASN Kidney Week 2023 organized by the American Society of Nephrology, in Philadelphia. The study of a drug named “Sotagliflozin”, which has been approved by the FDA in May as a heart failure treatment, also involved non-diabetic patients.
United States David Cherney University Of Toronto American Society Of Nephrology American Society York Alert
Source: aawsat.com
Sotagliflozin May Slow CKD Progression in Diabetic Kidney Disease
Sotagliflozin, a dual SGLT 1 and 2 inhibitor, appears as effective in reducing kidney outcomes as other SGLT2 inhibitors. An analysis of data from the SCORED trial supports that sotagliflozin can lower the risk for chronic kidney disease (CKD) progression.
New York United States David Cherney Deepakl Bhatt American Society Of Nephrology Kidney Week University Of Toronto
Source: endocrinologyadvisor.com
Sotagliflozin May Slow CKD Progression in Diabetic Kidney Disease
An analysis of data from the SCORED trial supports that sotagliflozin can lower the risk for chronic kidney disease (CKD) progression.
New York United States Deepakl Bhatt David Cherney University Of Toronto American Society Of Nephrology Kidney Week
Source: empr.com
Sotagliflozin May Slow CKD Progression in Diabetic Kidney Disease
Sotagliflozin, a dual SGLT 1 and 2 inhibitor, appears as effective in reducing kidney outcomes as other SGLT2 inhibitors. An analysis of data from the SCORED trial supports that sotagliflozin can lower the risk for chronic kidney disease (CKD) progression.
United States New York Deepakl Bhatt David Cherney American Society Of Nephrology Kidney Week Lexicon Pharmaceuticals Inc
Source: renalandurologynews.com
New Data Relating to Sotagliflozin to be Presented at the American Society of Nephrology (ASN) Kidney Week 2023 Annual Meeting
30.10.2023 - Presentations from four Lexicon-sponsored studies will highlight data supporting current and potential future use of sotagliflozin INPEFA (sotagliflozin) recently approved by FDA for treatment of heart failure THE WOODLANDS, Texas, Oct. 30, ... Seite 1
United States Vikas Sridhar Craig Granowitz David Cherney Large Us Integrated Health System Pennsylvania Convention Center
Source: wallstreet-online.de
Metabolite in urine predicts diabetic kidney
High urine levels of adenine, a metabolite produced in the kidney, were associated with a higher risk of kidney failure in three international research cohorts, a team from The University of Texas Health Science Center at San Antonio (also called UT Health San Antonio) reported.
Source: eurekalert.org
Episode 3: How to Reduce Renal Risk in Type 2 Diabetes
Want to prevent kidney disease progression in patients with type 2 diabetes? Join host Dr Silvio Inzucchi and nephrologist Dr David Cherney as they unpack the how and why behind current recommendations.
United States Silvio Inzucchi Medscape Indiscussion Kathy Tuttle David Cherney Hospital Research Institute
Source: medscape.com
What TL Insiders can look forward to in April
Step into spring with an exciting lineup of events all month long
Trevor Reichman El Mocambo David Cherney Knowledge Supper Club University Health Network Ajmera Transplant Centre
Source: torontolife.com